Nicollet Investment Management Inc. Cuts Holdings in Ionis Pharmaceuticals Inc (NASDAQ:IONS)

Nicollet Investment Management Inc. trimmed its holdings in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 2.7% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 10,340 shares of the company’s stock after selling 290 shares during the quarter. Nicollet Investment Management Inc.’s holdings in Ionis Pharmaceuticals were worth $625,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of IONS. Quest Capital Management Inc. ADV acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $36,000. Venturi Wealth Management LLC acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $40,000. Evoke Wealth LLC acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $41,000. Bradley Foster & Sargent Inc. CT acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at approximately $49,000. Finally, Harel Insurance Investments & Financial Services Ltd. boosted its stake in Ionis Pharmaceuticals by 553.3% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,078 shares of the company’s stock valued at $65,000 after acquiring an additional 913 shares in the last quarter. 86.49% of the stock is currently owned by institutional investors.

Several equities research analysts have weighed in on IONS shares. ValuEngine upgraded shares of Ionis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, December 3rd. BMO Capital Markets restated a “buy” rating and issued a $86.00 target price on shares of Ionis Pharmaceuticals in a research note on Thursday, January 30th. Needham & Company LLC restated a “buy” rating and issued a $87.00 target price on shares of Ionis Pharmaceuticals in a research note on Monday, December 23rd. Bank of America restated a “buy” rating and issued a $70.00 target price on shares of Ionis Pharmaceuticals in a research note on Tuesday, December 31st. Finally, Oppenheimer started coverage on shares of Ionis Pharmaceuticals in a research note on Thursday, December 12th. They issued a “buy” rating and a $77.00 target price for the company. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $74.92.

In other news, Director Joseph Klein III sold 812 shares of Ionis Pharmaceuticals stock in a transaction on Monday, November 25th. The shares were sold at an average price of $62.90, for a total transaction of $51,074.80. Following the completion of the sale, the director now directly owns 12,683 shares in the company, valued at $797,760.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Richard S. Geary sold 10,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $64.61, for a total transaction of $646,100.00. Insiders have sold 32,433 shares of company stock valued at $2,064,415 over the last quarter. Insiders own 2.40% of the company’s stock.

Shares of NASDAQ:IONS traded down $0.44 on Thursday, hitting $61.29. 520,562 shares of the company were exchanged, compared to its average volume of 829,451. Ionis Pharmaceuticals Inc has a 1-year low of $53.34 and a 1-year high of $86.58. The stock’s 50 day moving average price is $60.52 and its 200 day moving average price is $61.43. The company has a current ratio of 10.39, a quick ratio of 10.31 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $8.66 billion, a P/E ratio of 20.43, a price-to-earnings-growth ratio of 34.26 and a beta of 2.02.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Read More: Debt-To-Equity Ratio

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit